Role of ABRACL in the occurrence and development of malignant tumors

Abstract

Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui. Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.

References27

[1]	Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, plasticity, and tumor metastasis[J].Trends Cell Biol,2020,30(10): 764-776. DOI:10.1016/j.tcb.2020.07.003. pmid:32800658
[2]	Fares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited[J].Signal Transduct Target Ther,2020,5(1): 28. DOI:10.1038/s41392-020-0134-x.
[3]	Hyrskyluoto A, Vartiainen MK. Regulation of nuclear actin dynamics in development and disease[J].Curr Opin Cell Biol,2020,64: 18-24. DOI:10.1016/j.ceb.2020.01.012. pmid:32088545
[4]	Li J, Chen H. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells[J].Bioengineered,2022,13(4): 9019-9031. DOI:10.1080/21655979.2022.2056821. pmid:35341461
[5]	Lin J, Zhou T, Wang J. Solution structure of the human HSPC280 protein[J].Protein Sci,2011,20(1): 216-223. DOI:10.1002/pro.548. pmid:21082705
[6]	Pang TL, Chen FC, Weng YL, et al. Costars, a dictyostelium protein similar to the C-terminal domain of STARS, regulates the actin cytoskeleton and motility[J].J Cell Sci,2010,123(Pt 21): 3745-3755. DOI:10.1242/jcs.064709.
[7]	Hsiao BY, Chen CH, Chi HY, et al. Human costars family protein ABRACL modulates actin dynamics and cell migration and associates with tumorigenic growth[J].Int J Mol Sci,2021,22(4): 2037. DOI:10.3390/ijms22042037.
[8]	Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis[J].Nat Rev Cancer,2018,18(9): 533-548. DOI:10.1038/s41568-018-0038-z. pmid:30002479
[9]	Novikov NM, Zolotaryova SY, Gautreau AM, et al. Mutational drivers of cancer cell migration and invasion[J].Br J Cancer,2021,124(1): 102-114. DOI:10.1038/s41416-020-01149-0.
[10]	Ghouzlani A, Kandoussi S, Tall M, et al. Immune checkpoint inhibitors in human glioma microenvironment[J].Front Immunol,2021,12: 679425. DOI:10.3389/fimmu.2021.679425.
[11]	Youssef G, Miller JJ. Lower grade gliomas[J].Curr Neurol Neurosci Rep,2020,20(7): 21. DOI:10.1007/s11910-020-01040-8.
[12]	Liu B, Guan Y, Wang M, et al. ABRACL as a potential prognostic biomarker and correlates with immune infiltration in low-grade gliomas[J].Interdiscip Neurosurg,2022,30: 101618. DOI:10.1016/j.inat.2022.101618.
[13]	Brägelmann J, Lorenz C, Borchmann S, et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG -Ⅰ[J].Nat Commun,2021,12(1): 5505. DOI:10.1038/s41467-021-25728-8. pmid:34535668
[14]	Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment[J].Genes (Basel),2022,13(6): 960. DOI:10.3390/genes13060960.
[15]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J].Trends Cell Biol,2019,29(3): 212-226. DOI:10.1016/j.tcb.2018.12.001. pmid:30594349
[16]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl),2021,134(7): 783-791. DOI:10.1097/CM9.0000000000001474.
[17]	曹莎莎, 段丽娟, 周福有. 基于TCGA分析ABRACL在食管癌组织中的表达及机制[J].河南医学研究,2021,30(34): 6340-6344. DOI:10.3969/j.issn.1004-437X.2021.34.002.
[18]	Wang D, Liu H, Ren C, et al. High expression of ABRACL is associated with tumorigenesis and affects clinical outcome in gastric cancer[J].Genet Test Mol Biomarkers,2019,23(2): 91-97. DOI:10.1089/gtmb.2018.0195.
[19]	Fan S, Chen P, Li S. miR-145-5p inhibits the proliferation, migration, and invasion of esophageal carcinoma cells by targeting ABRACL[J].Biomed Res Int,2021,2021: 6692544. DOI:10.1155/2021/6692544.
[20]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[21]	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J].CA Cancer J Clin,2021,71(3): 264-279. DOI:10.3322/caac.21657.
[22]	Zhao Y, Li S, Childs EE, et al. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-α-induced liver injury[J].J Biol Chem,2001,276(29): 27432-27440. DOI:10.1074/jbc.M102465200. pmid:11369777
[23]	Ura B, Monasta L, Arrigoni G, et al. A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate[J].Oncotarget,2017,8(65): 109536-109545. DOI:10.18632/oncotarget.22725.
[24]	Deutsch EW, Omenn GS, Sun Z, et al. Advances and utility of the human plasma proteome[J].J Proteome Res,2021,20(12): 5241-5263. DOI:10.1021/acs.jproteome.1c00657. pmid:34672606
[25]	Saghaleyni R, Sheikh Muhammad A, Bangalore P, et al. Machine learning-based investigation of the cancer protein secretory pathway[J].PLoS Comput Biol,2021,17(4): e1008898. DOI:10.1371/journal.pcbi.1008898.
[26]	Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colo-rectal cancer[J].Int J Mol Sci,2022,23(2): 852. DOI:10.3390/ijms23020852.
[27]	Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration[J].F1000Res,2018,7:F1000 Faculty Rev-1796. DOI:10.12688/f1000research.15967.1.

Role of ABRACL in the occurrence and development of malignant tumors

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References27

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.